

SUPPLEMENTAL MATERIAL

Figure S1:




Figure S1: RyR1 in lymphocyte enriched population from CHF patients is phosphorylated at Ser2843, oxidized, and depleted of calstabin1. RyR1 was immunoprecipitated from cell lysate. Top panel: similar levels of RyR1 across samples. Second panel: Staining with anti-phosphoserine 2843 reveals increased phosphorylation at Ser2843 in CHF samples; third panel: Anti-DNP reveals increased channel oxidation in the CHF samples; Bottom panel: reduced levels of calstabin1 associated with the channels in CHF patients.

Figure S2:




Figure S2: RyR1 in lymphocyte enriched population from mice with CHF is phosphorylated at Ser2844, oxidized, and depleted of calstabin1. Treatment with S107 improves calstabin1 binding. RyR1 was immunoprecipitated from cell lysate. Top panel: similar levels of RyR1 across samples. Second panel: Staining with anti-phosphoserine 2844 reveals increased phosphorylation at Ser2844 in CHF and CHF treated with S107; third panel: Anti-DNP reveals increased RyR oxidation in the CHF samples; Bottom panel: reduced levels of calstabin1 associated with the channel in CHF mice, which is increased in mice treated with S107.